Teligent Inc. (TLGT)
Company Description
Teligent, Inc., formerly Igi Laboratories Inc, is a specialty generic pharmaceutical company.
Under the Company's own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada.
In the United States it marketed 35 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2018.
It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries.
It focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its contract manufacturing and formulation services business.
Its pipeline included 20 Abbreviated New Drug Application (ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products, as of December 31, 2018.

Country | United States |
IPO Date | Jul 30, 1981 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 142 |
CEO | Timothy Sawyer |
Contact Details
Address: 105 Lincoln Avenue Buena, NEW JERSEY United States | |
Website | http://www.teligent.com |
Stock Details
Ticker Symbol | TLGT |
Exchange | NASDAQ |
Fiscal Year | n/a |
Reporting Currency | USD |
CIK Code | 0000352998 |
CUSIP Number | 87960W203 |
ISIN Number | US87960W2035 |
Employer ID | 01-0355758 |
SIC Code | 2834 |
Key Executives
No executives data available.Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 14, 2022 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Oct 27, 2021 | 25-NSE | Filing |
Oct 15, 2021 | 8-K | Current Report |
Oct 08, 2021 | 3 | Filing |
Oct 07, 2021 | 3 | Filing |
Sep 27, 2021 | 8-K | Current Report |
Sep 24, 2021 | 8-K | Current Report |
Aug 16, 2021 | 10-Q | Quarterly Report |
Jul 22, 2021 | 4 | Filing |
Jul 22, 2021 | 4 | Filing |